Get started
Author

Chris J Torrance

Observed names: Chris Torrance, Chris Torrance,
OpenAlex ID: A5015727424
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
1999 · Fred Bunz, Paul M. Hwang, et al. · Journal of Clinical Investigation · 1,055
PDF
Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
2016 · Rowan E. Miller, Rachel Brough, et al. · Molecular Cancer Therapeutics · 89
TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1
2013 · Jane Zhao, Paul Lammers, et al. · Molecular Therapy · 62
PDF
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
2010 · Charles Swanton, James M Larkin, et al. · Genome Medicine · 45
PDF
Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
2014 · Theodora Katsila, Mercè Juliachs, et al. · Clinical Cancer Research · 25
PDF
Multiple Metabolic Alterations Exist in Mutant PI3K Cancers, but Only Glucose Is Essential as a Nutrient Source
2012 · Rebecca Foster, Sue Griffin, et al. · PLoS ONE · 16
PDF
Abstract 4289: 3-Dimensional growth reveals KRAS dependency.
2013 · Rebecca Foster, Clare Mudd, et al. · Cancer Research · 3
Abstract 1651: The use of ‘X-MAN’ isogenic cell lines to define PI3-kinase inhibitor activity profiles
2010 · John Goodall, Rebecca E. Foster, et al. · Cancer Research · 1
Supplementary Figures from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
PDF
Supplementary Table 12 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 3 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 11 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 2 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Figure legends and methods from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 10 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 1 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Data from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 8 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 6 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 7 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 1 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 4 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 9 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 5 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 5 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Works count: 50
Citation count: 1,296
H-index: 6
I10-index: 6
Year
Topic
Type